Diffusion Pharma files for $50M mixed shelf offering. May 16, 2019 4:50 PM ET. A mixed shelf offering is the ability to offer securities for sale with different size, price and terms which may be determined at the time of sale.
http://www.investorwords.com/11701/mixed_shelf.html#ixzz5oac7cWcF
The biggest obstacle that the company faced was the lack of funds. That has now been resolved. The company will do very good things with the new funds.
This expected new capital will fund the advancement of lead candidate trans sodium crocetinate (TSC) for the treatment of stroke and cancer.
Diffusion Pharmaceuticals is an absolute homerun once their products comer to market. We are talking a Google-like price tag. They offer an exciting new approach to the treatment of life-threatening diseases where cellular oxygen deprivation (known as “hypoxia”) is a key factor. This lack of oxygen is given different names, usually linked to the location of the oxygen deficiency.
Oxygen deprivation in the brain is a stroke; in the heart it’s a heart attack; in the legs, it’s peripheral arterial disease; systemically it may be respiratory. Lack of oxygen in a cancerous tumor causes something called treatment resistance. But wherever it is located and whatever it is called, the lack of oxygen in the human body carries severe consequences which may quickly become deadly.
Diffusion Pharmaceuticals is an absolute homerun once their products comer to market. We are talking a Google like price tag. They offer an exciting new approach to the treatment of those life-threatening diseases where cellular oxygen deprivation (known as “hypoxia”) is a key factor. This lack of oxygen is given different names, usually linked to the location of the oxygen deficiency.
Oxygen deprivation in the brain is a stroke; in the heart it’s a heart attack; in the legs, it’s peripheral arterial disease; systemically it may be respiratory. Lack of oxygen in a cancerous tumor causes something called treatment resistance. But wherever it is located and whatever it is called, the lack of oxygen in the human body carries severe consequences which may quickly become deadly.
Diffusion Pharmaceuticals Inc., formerly RestorGenex Corporation, is a clinical-stage biotechnology company. The Company is focused on developing standard-of-care treatments, including radiation therapy and chemotherapy.
The Company's lead product candidate, transcrocetinate sodium, also known as trans sodium crocetinate (TSC) is used in various cancer types, in which tumor oxygen deprivation (hypoxia) is known to diminish the effectiveness of treatments.
The Company's Diffusion's technology is targeted at overcoming treatment-resistance in solid cancerous tumors by combining its lead product candidate, TSC, with standard-of-care radiation and chemotherapy regimens, thus effecting a better patient survival outcome without the addition of harmful side effects.
Its clinical development plan targets TSC at the radiation and chemotherapy sensitization of hypoxic tumor types, with an initial focus on primary brain cancer (glioblastoma or GBM), pancreatic cancer, and brain metastases. 
ABOUT
Diffusion Pharmaceuticals is a Phase 3 clinical-stage biotech company dedicated to improving the outcome for cancer patients, stroke victims and others afflicted with life-threatening disease where cellular oxygen deprivation (known as ``hypoxia``) is a key factor
TECHNOLOGY
Our lead drug, Trans Sodium Crocetinate (“TSC”), targets the oxygen-deprived micro-environment of affected tissue, restoring life-giving oxygen to ischemic cells in stroke making cancer cells more vulnerable to the cancer-killing power of radiation and chemotherapy
INDICATIONS
Clinical targets include cancer, where a phase 3 trial in inoperable GBM brain cancer is enrolling patients, and acute ischemic stroke where we have received FDA approval for an innovative phase 2 protocol allowing in-ambulance administration of TSC
- Avg Vol (10-day): 41.0K
52-Wk Range: 1.83 - 11.00 Market Cap: 19.9M
.